Moderna
Featured in an OpenAI case study regarding their company-wide adoption of ChatGPT, demonstrating the success of a holistic approach to AI integration.
Every podcast mention of Moderna in one pod.
32 videos. Track how it's discussed, by whom, and what experts actually think.
Common Themes
Videos Mentioning Moderna
Maximizing AI in L&D: Ross Stevenson on adoption, strategy, and staying human
Big Think+
Featured in an OpenAI case study regarding their company-wide adoption of ChatGPT, demonstrating the success of a holistic approach to AI integration.
E113: DOJ tries to break up Google, vaccine questions, Ukraine escalation & more
All-In Podcast
Its COVID-19 vaccine is noted for having a potentially 30 times higher chance of causing myocarditis in young people, though still a low incidence rate.
E59: Twitter's content warning algo, equity audits, politicians trading stocks, Fed's next move
All-In Podcast
Pursued mRNA technology from Flagship Pioneering, struggled initially, but saw acceleration with COVID-19 vaccines.
E25: Biden's vaccine mandate, "equity" in distribution, NFT speculation, impact of inflation & more
All-In Podcast
Mentioned in the context of vaccine inventory forecasts.
E13: SPACsgiving Special! Vaccine news, innovation vs regulation, fixing higher ed, challenge trials
All-In Podcast
A company developing a COVID-19 vaccine with high efficacy, discussed in the context of Operation Warp Speed and trial delays.
Balaji Srinivasan: How to Fix Government, Twitter, Science, and the FDA | Lex Fridman Podcast #331
Lex Fridman
Its vaccine was available early in the pandemic, highlighting the potential for challenge trials to expedite vaccine information.
Essential Startup Advice During a Pandemic
Y Combinator
A company whose vaccine candidate showed over 90% effectiveness, contributing to optimism about the pandemic's end.
Scott Galloway: AI Wasn’t Built For You. The Rich Don’t Need You Anymore!
The Diary Of A CEO
Pharmaceutical and biotechnology company, whose stock value is noted as being down 90%, illustrating that even significant innovations like vaccines don't always lead to sustained shareholder value for individual companies.